These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 25769011)

  • 21. Studies on the reactivity of organometallic Ru-, Rh- and Os-pta complexes with DNA model compounds.
    Dorcier A; Hartinger CG; Scopelliti R; Fish RH; Keppler BK; Dyson PJ
    J Inorg Biochem; 2008; 102(5-6):1066-76. PubMed ID: 18086499
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Competitive binding sites of a ruthenium arene anticancer complex on oligonucleotides studied by mass spectrometry: ladder-sequencing versus top-down.
    Wu K; Hu W; Luo Q; Li X; Xiong S; Sadler PJ; Wang F
    J Am Soc Mass Spectrom; 2013 Mar; 24(3):410-20. PubMed ID: 23404464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metallomics for drug development: a further insight into intracellular activation chemistry of a ruthenium(III)-based anticancer drug gained using a multidimensional analytical approach.
    Matczuk M; Prządka M; Aleksenko SS; Czarnocki Z; Pawlak K; Timerbaev AR; Jarosz M
    Metallomics; 2014 Jan; 6(1):147-53. PubMed ID: 24247321
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Competition between glutathione and guanine for a ruthenium(II) arene anticancer complex: detection of a sulfenato intermediate.
    Wang F; Xu J; Habtemariam A; Bella J; Sadler PJ
    J Am Chem Soc; 2005 Dec; 127(50):17734-43. PubMed ID: 16351102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trans-cis-cis-[RuCl2(DMSO)2(2-amino-5-methyl-thiazole)2], (PMRu52), a novel ruthenium(II) compound acting as a strong inhibitor of cathepsin B.
    Mura P; Camalli M; Casini A; Gabbiani C; Messori L
    J Inorg Biochem; 2010 Feb; 104(2):111-7. PubMed ID: 19939460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification and discrimination of binding sites of an organoruthenium anticancer complex to single-stranded oligonucleotides by mass spectrometry.
    Liu S; Wu K; Zheng W; Zhao Y; Luo Q; Xiong S; Wang F
    Analyst; 2014 Sep; 139(18):4491-6. PubMed ID: 25028701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biomolecule binding vs. anticancer activity: reactions of Ru(arene)[(thio)pyr-(id)one] compounds with amino acids and proteins.
    Meier SM; Hanif M; Kandioller W; Keppler BK; Hartinger CG
    J Inorg Biochem; 2012 Mar; 108():91-5. PubMed ID: 22420927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anthracene-tethered ruthenium(II) arene complexes as tools to visualize the cellular localization of putative organometallic anticancer compounds.
    Nazarov AA; Risse J; Ang WH; Schmitt F; Zava O; Ruggi A; Groessl M; Scopelitti R; Juillerat-Jeanneret L; Hartinger CG; Dyson PJ
    Inorg Chem; 2012 Mar; 51(6):3633-9. PubMed ID: 22394115
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of (eta6-arene)ruthenium(II) protein binding sites in E. coli cells by combined multidimensional liquid chromatography and ESI tandem mass spectrometry: specific binding of [(eta6-p-cymene)RuCl2 (DMSO)] to stress-regulated proteins and to helicases.
    Will J; Kyas A; Sheldrick WS; Wolters D
    J Biol Inorg Chem; 2007 Aug; 12(6):883-94. PubMed ID: 17516097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterizing activation mechanisms and binding preferences of ruthenium metallo-prodrugs by a competitive binding assay.
    Artner C; Holtkamp HU; Hartinger CG; Meier-Menches SM
    J Inorg Biochem; 2017 Dec; 177():322-327. PubMed ID: 28739166
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular mass spectrometry in metallodrug development: a case of mapping transferrin-mediated transformations for a ruthenium(III) anticancer drug.
    Jarosz M; Matczuk M; Pawlak K; Timerbaev AR
    Anal Chim Acta; 2014 Dec; 851():72-7. PubMed ID: 25440667
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of ion mobility mass spectrometry and a collision cross-section algorithm to study an organometallic ruthenium anticancer complex and its adducts with a DNA oligonucleotide.
    Williams JP; Lough JA; Campuzano I; Richardson K; Sadler PJ
    Rapid Commun Mass Spectrom; 2009 Nov; 23(22):3563-9. PubMed ID: 19844963
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and characterization of ruthenium(II)-pyridylamine complexes with catechol pendants as metal binding sites.
    Kojima T; Hirasa N; Noguchi D; Ishizuka T; Miyazaki S; Shiota Y; Yoshizawa K; Fukuzumi S
    Inorg Chem; 2010 Apr; 49(8):3737-45. PubMed ID: 20329711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Picolinate ruthenium(II)-arene complex with in vitro antiproliferative and antimetastatic properties: comparison to a series of ruthenium(II)-arene complexes with similar structure.
    Gligorijević N; Aranđelović S; Filipović L; Jakovljević K; Janković R; Grgurić-Šipka S; Ivanović I; Radulović S; Tešić ZLj
    J Inorg Biochem; 2012 Mar; 108():53-61. PubMed ID: 22266461
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DNA structural distortions induced by ruthenium-arene anticancer compounds.
    Gossens C; Tavernelli I; Rothlisberger U
    J Am Chem Soc; 2008 Aug; 130(33):10921-8. PubMed ID: 18651736
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural and functional characterization of an organometallic ruthenium complex as a potential myorelaxant drug.
    Trobec T; Žužek MC; Sepčić K; Kladnik J; Kljun J; Turel I; Benoit E; Frangež R
    Biomed Pharmacother; 2020 Jul; 127():110161. PubMed ID: 32380389
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tuning the hydrophobicity of ruthenium(II)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy.
    Scolaro C; Chaplin AB; Hartinger CG; Bergamo A; Cocchietto M; Keppler BK; Sava G; Dyson PJ
    Dalton Trans; 2007 Nov; (43):5065-72. PubMed ID: 17992291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The contrasting chemistry and cancer cell cytotoxicity of bipyridine and bipyridinediol ruthenium(II) arene complexes.
    Bugarcic T; Habtemariam A; Stepankova J; Heringova P; Kasparkova J; Deeth RJ; Johnstone RD; Prescimone A; Parkin A; Parsons S; Brabec V; Sadler PJ
    Inorg Chem; 2008 Dec; 47(24):11470-86. PubMed ID: 19007206
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cellular delivery of pyrenyl-arene ruthenium complexes by a water-soluble arene ruthenium metalla-cage.
    Furrer MA; Schmitt F; Wiederkehr M; Juillerat-Jeanneret L; Therrien B
    Dalton Trans; 2012 Jun; 41(24):7201-11. PubMed ID: 22506276
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of mass spectrometry and other techniques for probing interactions between metal complexes and DNA.
    Urathamakul T; Waller DJ; Beck JL; Aldrich-Wright JR; Ralph SF
    Inorg Chem; 2008 Aug; 47(15):6621-32. PubMed ID: 18611003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.